University Medical Center New Orleans

Summary

University Medical Center New Orleans is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Prostate Cancer and other specialties. University Medical Center New Orleans is involved with conducting 255 clinical trials across 450 conditions. There are 30 research doctors associated with this hospital, such as Scott E. Delacroix, Brian C. Boulmay, Augusto C. Ochoa, and Jyotsna Fuloria.

Top PIs

Clinical Trials running at University Medical Center New Orleans

Breast Cancer

Lung Cancer

Breast cancer

Ovarian Cancer

Skin Cancer

Cancer

Uterine Cancer

Prostate Cancer

Pancreatic Cancer

Esophageal cancer

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria